Topiramate therapy for paroxysmal kinesigenic choreoathetosis.

Yuan-Gui Huang,Yun-Chun Chen,Fang Du,Rui Li,Ge-Lin Xu,Wen Jiang,Jing Huang
DOI: https://doi.org/10.1002/mds.20283
IF: 9.698
2005-01-01
Movement Disorders
Abstract:We observed the clinical efficacy of topiramate for paroxysmal kinesigenic choreoathetosis (PKC). Topiramate was administered as a monotherapy with titrated dosages to 8 patients with PKC. Target daily dose of topiramate was 100 to 200 mg; the follow-up period ranged from 8 months to 2 years. All of the patients became attack-free, and side effects were mild. The results show that topiramate is effective as a monotherapy for treating patients with PKC. The response to topiramate indicates that the disease may be caused by an ion channel defect. (C) 2004 Movement Disorder Society
What problem does this paper attempt to address?